Study name/code (NCT) | Study phase | Type of Cancer | Treatment | Patients evaluated for response | Time to first tumor assessment (weeks) | ORR by RECIST 1.1 criteria | ORR by immune-related response criteria | Patients treated beyond progression | Response rate after initial PD | First author and date of publication |
---|---|---|---|---|---|---|---|---|---|---|
CheckMate-012 (NCT01454102) | 1 | NSCLC | Nivolumab plus standard chemotherapy | 56 | 10a | 24 (42.9%) | Not reported | Not reported | 1 (1.8%) | Rizvi 2016 [80] |
GP28328 (NCT01633970) | 1b | Breast cancer | Atezolizumab plus chemotherapy | 33 | 8 | 13 (39.4%) | Not reported | 6 (18.2%) | 3 (9.1%) | Adams 2019 [81] |
PembroPlus (NCT02331251) | 1b/2 | Pancreatic adenocarcinoma | Pembrolizumab plus gemcitabine and nab-paclitaxel | 15 | Not reported | 3 (20.0%) | 3 (20.0%)a | Not reported | 0 (0.0%)b | Weiss 2017 [82] |
NCI-2015-01310 (NCT02538510) | 2 | HNSCC and salivary gland cancer | Pembrolizumab plus vorinostat | 50 | 9 | 12 (24.0%) | Not reported | 12 (24.0%) | 1 (2.0%)c | Rodriguez 2019 [83] |
PEMBROSARC (NCT02406781) | 2 | Sarcomas | Pembrolizumab plus CP | 50 | 6 | 0 (0.0%) | 1 (2.0%) | Not reported | 1 (2.0%) | Toulmonde 2018 [84] |